JP2004532032A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004532032A5 JP2004532032A5 JP2002585635A JP2002585635A JP2004532032A5 JP 2004532032 A5 JP2004532032 A5 JP 2004532032A5 JP 2002585635 A JP2002585635 A JP 2002585635A JP 2002585635 A JP2002585635 A JP 2002585635A JP 2004532032 A5 JP2004532032 A5 JP 2004532032A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- substitution
- pharmaceutical composition
- cell
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims 18
- 102000004196 processed proteins & peptides Human genes 0.000 claims 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims 18
- 238000006467 substitution reaction Methods 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 238000000034 method Methods 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 1
- 206010019663 Hepatic failure Diseases 0.000 claims 1
- 206010067125 Liver injury Diseases 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 238000006471 dimerization reaction Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 229960002897 heparin Drugs 0.000 claims 1
- 229920000669 heparin Polymers 0.000 claims 1
- 231100000234 hepatic damage Toxicity 0.000 claims 1
- 230000008818 liver damage Effects 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 208000007903 liver failure Diseases 0.000 claims 1
- 231100000835 liver failure Toxicity 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000035409 positive regulation of cell proliferation Effects 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0110430.6A GB0110430D0 (en) | 2001-04-27 | 2001-04-27 | Protein variants and uses thereof |
| PCT/GB2002/001941 WO2002088354A1 (en) | 2001-04-27 | 2002-04-29 | The nk1 fragment of hepatocyte growth factor/scatter factor (hgf/sf) and variants thereof, and their use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010208693A Division JP2011045370A (ja) | 2001-04-27 | 2010-09-17 | 肝細胞増殖因子／細胞分散因子（ｈｇｆ／ｓｆ）のｎｋ１断片およびそれらの変異体、ならびにそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004532032A JP2004532032A (ja) | 2004-10-21 |
| JP2004532032A5 true JP2004532032A5 (enExample) | 2005-12-22 |
| JP4637452B2 JP4637452B2 (ja) | 2011-02-23 |
Family
ID=9913640
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002585635A Expired - Fee Related JP4637452B2 (ja) | 2001-04-27 | 2002-04-29 | 肝細胞増殖因子／細胞分散因子（ｈｇｆ／ｓｆ）のｎｋ１断片およびそれらの変異体、ならびにそれらの使用 |
| JP2010208693A Pending JP2011045370A (ja) | 2001-04-27 | 2010-09-17 | 肝細胞増殖因子／細胞分散因子（ｈｇｆ／ｓｆ）のｎｋ１断片およびそれらの変異体、ならびにそれらの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010208693A Pending JP2011045370A (ja) | 2001-04-27 | 2010-09-17 | 肝細胞増殖因子／細胞分散因子（ｈｇｆ／ｓｆ）のｎｋ１断片およびそれらの変異体、ならびにそれらの使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US7179786B2 (enExample) |
| EP (1) | EP1381681B1 (enExample) |
| JP (2) | JP4637452B2 (enExample) |
| AT (1) | ATE368741T1 (enExample) |
| AU (1) | AU2002251337B2 (enExample) |
| CA (1) | CA2440775C (enExample) |
| DE (1) | DE60221510T2 (enExample) |
| DK (1) | DK1381681T3 (enExample) |
| ES (1) | ES2291460T3 (enExample) |
| GB (1) | GB0110430D0 (enExample) |
| WO (1) | WO2002088354A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0110430D0 (en) * | 2001-04-27 | 2001-06-20 | Medical Res Council | Protein variants and uses thereof |
| US20050107296A1 (en) * | 2001-10-31 | 2005-05-19 | Institut Des Vaisseaux Et Du Sang | Isolated peptide of the hepatocyte growth factor and its variants, preparation method and therapeutic use as anti-angiogenic agents |
| AT412785B (de) * | 2003-12-04 | 2005-07-25 | Kungl Andreas J Dr | Gag-bindungsproteine |
| US7563570B2 (en) | 2004-10-29 | 2009-07-21 | Pangaea Biotech | Method of determining a chemotherapeutic regimen for non small cell lung cancer based on BRCA1 expression |
| US20090215686A1 (en) * | 2007-03-05 | 2009-08-27 | Huaqiang Eric Xu | Nk1-based polypeptides and related methods |
| US8247374B2 (en) | 2007-11-09 | 2012-08-21 | New York Medical College | Methods and compositions for the repair and/or regeneration of damaged myocardium using cytokines and variants thereof |
| CN103037892A (zh) * | 2010-02-22 | 2013-04-10 | 布里格姆妇女医院 | 诱导血管生成的组合物和方法 |
| US9556248B2 (en) | 2010-03-19 | 2017-01-31 | The Board Of Trustees Of The Leland Stanford Junior University | Hepatocyte growth factor fragments that function as potent met receptor agonists and antagonists |
| DK2638173T3 (da) | 2010-11-08 | 2019-09-30 | Univ Leland Stanford Junior | Fusionsproteiner omfattende et manipuleret knottin-peptid og anvendelser deraf |
| WO2013037521A1 (en) | 2011-09-16 | 2013-03-21 | Medical Research Council | Modified hgf-1k1 polypeptide |
| WO2013037520A1 (en) | 2011-09-16 | 2013-03-21 | Glaxo Group Limited | Modified hgf-1k1 polypeptide |
| PT3247719T (pt) * | 2015-01-21 | 2019-12-23 | Univ Degli Studi Di Pavia | Proteínas agonistas do receptor met |
| MX2018015684A (es) | 2016-06-17 | 2019-08-29 | Magenta Therapeutics Inc | Composiciones y metodos para el agotamiento de celulas cd117. |
| GB201611123D0 (en) * | 2016-06-27 | 2016-08-10 | Euremab Srl | Anti met antibodiesand uses thereof |
| IL268058B2 (en) | 2017-01-20 | 2023-09-01 | Magenta Therapeutics Inc | Compositions and methods for depleting cd137 plus cells |
| IT201800000535A1 (it) | 2018-01-03 | 2019-07-03 | Procedimenti per la cura del cancro. | |
| CN109535243B (zh) | 2019-01-07 | 2019-09-24 | 北京诺思兰德生物技术股份有限公司 | 人肝细胞生长因子突变体及其应用 |
| CN119613527B (zh) * | 2024-12-30 | 2026-02-06 | 江苏三仪生物工程有限公司 | 鸡肝细胞生长因子的截短突变体及其在防治肝脏相关疾病方面的用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5594115A (en) * | 1990-04-09 | 1997-01-14 | Pharmacia & Upjohn Company | Process of purifying recombinant proteins and compounds useful in such process |
| US6566098B1 (en) | 1990-09-14 | 2003-05-20 | The United States Of America As Represented By The Department Of Health And Human Services | DNA encoding truncated hepatocyte growth factor variants |
| WO1993023541A1 (en) | 1992-05-18 | 1993-11-25 | Genentech, Inc. | Hepatocyte growth factor variants |
| JP4006058B2 (ja) * | 1997-03-11 | 2007-11-14 | 第一三共株式会社 | 多臓器不全予防及び／又は治療剤 |
| GB0110430D0 (en) * | 2001-04-27 | 2001-06-20 | Medical Res Council | Protein variants and uses thereof |
-
2001
- 2001-04-27 GB GBGB0110430.6A patent/GB0110430D0/en not_active Ceased
-
2002
- 2002-04-29 JP JP2002585635A patent/JP4637452B2/ja not_active Expired - Fee Related
- 2002-04-29 WO PCT/GB2002/001941 patent/WO2002088354A1/en not_active Ceased
- 2002-04-29 ES ES02720271T patent/ES2291460T3/es not_active Expired - Lifetime
- 2002-04-29 DE DE60221510T patent/DE60221510T2/de not_active Expired - Lifetime
- 2002-04-29 US US10/475,616 patent/US7179786B2/en not_active Expired - Fee Related
- 2002-04-29 DK DK02720271T patent/DK1381681T3/da active
- 2002-04-29 AU AU2002251337A patent/AU2002251337B2/en not_active Ceased
- 2002-04-29 AT AT02720271T patent/ATE368741T1/de not_active IP Right Cessation
- 2002-04-29 CA CA2440775A patent/CA2440775C/en not_active Expired - Fee Related
- 2002-04-29 EP EP02720271A patent/EP1381681B1/en not_active Expired - Lifetime
-
2007
- 2007-01-26 US US11/627,761 patent/US7795214B2/en not_active Expired - Fee Related
-
2010
- 2010-08-17 US US12/858,189 patent/US8232258B2/en not_active Expired - Fee Related
- 2010-09-17 JP JP2010208693A patent/JP2011045370A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4620444B2 (ja) | Ｇｌｐ−１の類似体 | |
| KR102367997B1 (ko) | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 | |
| Adams et al. | The thrombospondins | |
| KR970701776A (ko) | 형질전환 성장 인자 알파 에이치1(Transforming growth factor alpha H1) | |
| JP2006077022A (ja) | Ｇｌｐ−１の類似体 | |
| WO2003040307A3 (en) | Heteromultimeric tnf ligand family members | |
| EA020091B1 (ru) | Аналоги глюкозозависимого инсулинотропного полипептида (gip), модифицированные по n-концу | |
| JP2012518420A5 (enExample) | ||
| CY1111703T1 (el) | Αντισωματα του αντι-c5 συστατικου του συστηματος συμπληρωματος και η χρηση τους | |
| JP2018538356A5 (enExample) | ||
| JP2010174016A (ja) | Ｇｌｐ−１類似体 | |
| JP2007524579A (ja) | Ｇｌｐ−１の類似体 | |
| JP2006506942A5 (enExample) | ||
| TR201900959T4 (en) | COMPOSITIONS AND ITS MEDICAL USE. | |
| JP2006507229A5 (enExample) | ||
| JP2012524725A5 (enExample) | ||
| JP2004522748A5 (enExample) | ||
| EP4282490A3 (en) | Fibronectin-binding peptides for use in tumor or fibrosis diagnosis and therapy | |
| JP2004537284A5 (enExample) | ||
| EP2096120A3 (en) | Use of secreted protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome | |
| JP2015515855A5 (enExample) | ||
| CA2719940A1 (en) | Methods for treating acute myocardial infarction | |
| EP1814577B1 (en) | Use of baff to treat sepsis | |
| JP2004073182A5 (enExample) | ||
| JP4520951B2 (ja) | インスリン分泌誘導剤及びインスリン分泌誘導組成物 |